Literature DB >> 21338258

The debate is over: accelerator MS provides the route to better drug-development paradigms/protocols.

Dennis A Smith.   

Abstract

Mesh：

Year:  2011        PMID： 21338258     DOI： 10.4155/bio.11.9

Source DB:  PubMed          Journal:  Bioanalysis        ISSN： 1757-6180            Impact factor:   2.681


× No keyword cloud information.
  3 in total

1.  Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.

Authors:  David W Boulton; Sreeneeranj Kasichayanula; Chi Fung Anther Keung; Mark E Arnold; Lisa J Christopher; Xiaohui Sophia Xu; Frank Lacreta
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 2.  Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.

Authors:  Heather A Enright; Michael A Malfatti; Maike Zimmermann; Ted Ognibene; Paul Henderson; Kenneth W Turteltaub
Journal:  Chem Res Toxicol       Date:  2016-10-11       Impact factor: 3.739

3.  Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.

Authors:  Sangeeta Raje; Ernesto Callegari; Vaishali Sahasrabudhe; Alfin Vaz; Haihong Shi; Eric Fluhler; Eric J Woolf; Klaas Schildknegt; Kyle Matschke; Christine Alvey; Susan Zhou; Dimitris Papadopoulos; Robert Fountaine; Didier Saur; Steven G Terra; Lloyd Stevens; Daniel Gaunt; David L Cutler
Journal:  Clin Transl Sci       Date:  2018-03-25       Impact factor: 4.689
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.